← Leaderboards
Monika Fleckenstein
University Of Utah
$2,182,207
Attributed
$2,730,832
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $807.1K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,730,832 · 3
By mechanism
R01$2,578,250 · 2
P30$152,582 · 1
Top collaborators
- Steffen Schmitz-Valckenberg3 shared
Most similar at University Of Utah
Same institution · by research overlap
- Wolfgang Baehr$13,933,029
- Robert E Marc$15,329,042
- Jun Yang$6,508,633
- Yingbin Fu$5,386,081
- Steffen Schmitz-Valckenberg$548,625
Others in their field
Other Rising Stars on “Fundus”
- Karyn Jonas · Siloam Vision, Inc.$1,420,898
- Jefferson James Doyle · Johns Hopkins University$950,092
- Fred Kaggwa · Mbarara University/Science/ Technology$831,762
- Christopher Dale Conrady · University Of Nebraska Medical Center$707,693
- Steffen Schmitz-Valckenberg · University Of Utah$548,625
- Chase Ludwig · Stanford University$548,296
Research focus
FundusClinical ResearchAreaVisionPersonalized MedicineRetinal ImagingFutureProspectivePrognosisPreventResolutionTissuesAge Related Macular DegenerationBiological MarkersData SetBlindnessNonexudative Age-Related Macular DegenerationDisease ProgressionPerimetryOptical Coherence TomographyResearch Project GrantsProtocols DocumentationAngiographyIn Vivo
Grant awards (8)
Progression of Early Atrophic Lesions in Age-related Macular degeneration$327,250
R01 · FY2025 · EY
The Impact of Non-Exudative Type 1 Macular Neovascularization (MNV) on Age-related Macular Degeneration (AMD) Progression$327,250
R01 · FY2025 · EY · contact PI
Imaging Core$152,582
P30 · FY2025 · EY · contact PI
Progression of Early Atrophic Lesions in Age-related Macular degeneration$385,000
R01 · FY2024 · EY
The Impact of Non-Exudative Type 1 Macular Neovascularization (MNV) on Age-related Macular Degeneration (AMD) Progression$385,000
R01 · FY2024 · EY · contact PI
The Impact of Non-Exudative Type 1 Macular Neovascularization (MNV) on Age-related Macular Degeneration (AMD) Progression$385,000
R01 · FY2023 · EY · contact PI
Progression of Early Atrophic Lesions in Age-related Macular degeneration$385,000
R01 · FY2023 · EY
The Impact of Non-Exudative Type 1 Macular Neovascularization (MNV) on Age-related Macular Degeneration (AMD) Progression$383,750
R01 · FY2022 · EY · contact PI